Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.65
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.65
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.36 - $1.83
Previous CloseN/A
Volume2.02M
Average Volume (3M)2.51M
Market Cap
$699.07M
Enterprise Value$726.98M
Total Cash (Recent Filing)$96.23M
Total Debt (Recent Filing)$62.24M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Apr 30, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding423,680,600
10 Day Avg. Volume2,597,600
30 Day Avg. Volume2,511,386
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue14.60
Enterprise Value/Gross Profit14.77
Enterprise Value/Ebitda-17.04
Forecast
1Y Price Target
$3.83Price Target Upside132.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$34.04M
Bulls Say, Bears Say
Bulls Say
Diabetic Peripheral Neuropathic Pain DevelopmentFavorable End-of-Phase 2 feedback combined with Phase 2b results identifying a tolerable once-daily dose supports pilavapadin as a non-opioid therapy and increases the likelihood of late-stage partnerships and broader development.
Hypertrophic Cardiomyopathy Clinical ProgressPositive initial data from the SONATA program in both obstructive and non-obstructive hypertrophic cardiomyopathy suggest a differentiated safety and functional profile that could establish a first-in-class therapy and expand treatment adoption.
Partnership And LicensingAdvancement of LX9851 into first-in-human studies by a global pharmaceutical partner increases milestone visibility and creates potential for significant milestone payments and royalty revenue tied to obesity and metabolic disorder indications.
Bears Say
Regulatory And Execution RiskCommercial and clinical progress depends on regulatory approvals and partner actions, producing execution risk that could delay launches or reduce projected revenue if key milestones are missed.
Renal Function Efficacy LimitationsClinical benefits appear strongest in patients with preserved kidney function while patients with impaired kidney function experience smaller effects, which could narrow the eligible patient pool and limit commercial uptake.
Safety Data UncertaintyOngoing independent studies collecting diabetic ketoacidosis and drug exposure data create uncertainty around safety outcomes that regulators will weigh for any resubmission, raising the possibility of additional data requests or delays.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.36 and its highest was $1.83 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $699.07M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 32 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Mar 05, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.069 by $0.029.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.03.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 423,680,600 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.069. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (132.12% Upside)
$3.83 (132.12% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 143.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
375.50%
12-Months-Change
Fundamentals
Return on Equity
-41.94%
Trailing 12-Months
Asset Growth
-38.01%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program-level progress and meaningful financial discipline: multiple regulatory and clinical catalysts are in motion (Sonata enrollment, potential Zynquista resubmission, pilovapitan Phase III readiness, LX9851 milestones), operating expenses and losses were substantially reduced, and the company strengthened its cash position post-period. Offsetting risks include reliance on third-party STENO-1 data for Zynquista, modest INPEFA sales, a reduced year-end cash balance prior to the subsequent raise, and the need to partner to advance pilovapitan into Phase III. On balance, the positive pipeline and financial improvements materially outweigh the remaining execution and external-data risks.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$3.83
▲(132.12% Upside)
Technical Analysis
Ownership Overview
22.92% Insiders
7.18% Mutual Funds
43.05% Other Institutional Investors
24.25% Public Companies and
Individual Investors